These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1818 related items for PubMed ID: 28515940

  • 1. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 2. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 3. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan 19; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
    Goff CB, Plaxe SC, White W, Dasanu CA.
    J Oncol Pharm Pract; 2023 Jul 19; 29(5):1259-1263. PubMed ID: 36734125
    [Abstract] [Full Text] [Related]

  • 5. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug 19; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 6. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S, Kuriyama A, Tachibana H.
    J Emerg Med; 2021 Mar 19; 60(3):342-344. PubMed ID: 33097350
    [Abstract] [Full Text] [Related]

  • 7. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Jun 29; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 11. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N, Lamine F.
    BMC Endocr Disord; 2019 Dec 23; 19(1):144. PubMed ID: 31870373
    [Abstract] [Full Text] [Related]

  • 12. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan 23; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 13. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
    Seo JH, Lim T, Ham A, Kim YA, Lee M.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30456. PubMed ID: 36107574
    [Abstract] [Full Text] [Related]

  • 14. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr 02; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
    Daetwyler E, Zippelius A, Danioth S, Donath MY, Gut L.
    Front Immunol; 2023 Apr 02; 14():1248919. PubMed ID: 37965350
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T.
    Front Endocrinol (Lausanne); 2024 Apr 02; 15():1407192. PubMed ID: 38841300
    [Abstract] [Full Text] [Related]

  • 19. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
    Obara K, Masuzawa M, Amoh Y.
    J Dermatol; 2018 May 02; 45(5):587-591. PubMed ID: 29352490
    [Abstract] [Full Text] [Related]

  • 20. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P, Liu S, Cao H.
    J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 91.